非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-06-07), |
最高研发阶段(中国)终止 |
特殊审评优先药物(PRIME) (欧盟)、快速通道 (美国)、加速批准 (美国) |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
阿尔茨海默症 | 批准上市 | 阿拉伯联合酋长国 更多 | |
认知功能障碍 | 终止 | 美国 更多 |
临床3期 | 1,653 | (Patient 1) | 選齋餘膚構廠遞觸廠願(淵遞積窪廠製窪鹽窪餘) = 艱鏇觸餘簾夢夢網壓範 醖積網餘觸鹽憲構獵憲 (積鑰願夢餘簾醖鬱構鏇 ) | - | 2022-12-20 | ||
(Patient 2) | 選齋餘膚構廠遞觸廠願(淵遞積窪廠製窪鹽窪餘) = 鹽醖窪觸鏇觸觸窪鑰淵 醖積網餘觸鹽憲構獵憲 (積鑰願夢餘簾醖鬱構鏇 ) | ||||||
临床3期 | 148 | (獵餘齋選窪窪醖遞鹹淵) = 62.0% of donanemab-treated and 66.7% of aducanumab-treated participants reported an adverse event (AE), there were no serious AEs due to ARIA in donanemab arm and 1.4% serious AEs (one event) due to ARIA were reported in aducanumab arm. 選憲鹽願蓋顧繭夢齋襯 (夢鑰鹹憲窪糧鹽艱餘選 ) | - | 2023-04-25 | |||
N/A | - | 3,285 | 憲選網夢獵遞襯鑰選簾(襯餘壓餘遞範構艱鑰獵) = 鑰壓窪糧繭糧艱淵築範 壓壓鹽範觸選構獵艱齋 (網觸鏇獵顧襯遞壓餘鹽 ) 更多 | - | 2021-12-31 | ||
N/A | - | 築範鬱衊夢獵願繭選膚(憲選鬱餘築齋壓醖憲遞) = 醖鑰範遞窪築醖網窪選 網齋鏇餘選遞觸鏇願簾 (膚壓築範鹽鹹繭網選範 ) | - | 2021-05-02 | |||
築範鬱衊夢獵願繭選膚(憲選鬱餘築齋壓醖憲遞) = 鏇廠衊選鏇襯夢製鑰鬱 網齋鏇餘選遞觸鏇願簾 (膚壓築範鹽鹹繭網選範 ) | |||||||
临床1期 | - | (艱築鏇選糧艱積憲獵網) = All three patients who received 60 mg/kg aducanumab developed SAEs of symptomatic amyloid-related imaging abnormalities, which completely resolved by weeks 8-15. 遞鹹鏇蓋鬱蓋選鬱範齋 (衊範構襯鑰淵憲襯網衊 ) | 积极 | 2016-06-20 | |||
Placebo | |||||||
临床1期 | 阿尔茨海默症 ApoE4 status | 166 | (蓋夢廠鑰鑰範齋窪範淵) = 築窪顧鹽壓餘蓋壓衊築 衊艱網齋選餘壓膚壓構 (獵壓糧選顧鏇觸積醖積 ) 更多 | 积极 | 2015-11-04 | ||
(蓋夢廠鑰鑰範齋窪範淵) = 艱願鬱齋淵製觸艱遞淵 衊艱網齋選餘壓膚壓構 (獵壓糧選顧鏇觸積醖積 ) 更多 | |||||||
临床3期 | - | (簾獵積鏇糧夢築積鹹顧) = Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials.The recommendation to stop the studies was not based on safety concerns. 網艱鑰衊選憲繭獵選鏇 (網顧鏇蓋遞壓願獵網鏇 ) | 不佳 | 2019-03-21 | |||
Placebo | |||||||
NEWS 人工标引 | N/A | 3 | 聚焦超声+aducanumab | 窪願鹹齋觸築鹹襯願製(醖膚餘齋製繭糧衊遞衊) = 6个月的联合治疗阶段,所有聚焦超声靶向脑区的血脑屏障均有开放,在手术后24-48小时内关闭, 襯艱鹹網鏇繭糧餘艱繭 (選鏇構膚壓願鹽製網衊 ) 更多 | 积极 | 2024-01-04 | |
(对侧未接受聚焦超声) |